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Mutation- and Tissue-Specific Alterations of RPGR Transcripts
Abstract
PURPOSE. The majority of patients with X chromosome-linked retinitis pigmentosa (XlRP) carry
mutations in the RPGR gene. The authors studied whether patients with RPGR mutations show
additional splice defects that may interfere with RPGR properties. METHODS. Patient-derived cell lines
with RPGR mutations were raised in suspension. To verify mutations, direct sequencing of PCR
products was performed. Patient-specific alterations in RPGR splicing were analyzed by RT-PCR and
confirmed by sequencing. Tissue-specific expression levels of RPGR splice variants were quantified by
real-time PCR using pools of different human donor tissues. RESULTS. The authors analyzed the
splicing of RPGR in seven RP patient-derived lymphoblastoid cell lines carrying hemizygous RPGR
mutations. In three patient cell lines, they identified and characterized splice defects that were present in
addition to a mutation. These splice defects were likely to interfere with normal RPGR properties.
Furthermore, they identified four novel RPGR transcripts, either containing a new exon termed 11a or
skipping the constitutive exons 12, 14, and 15. Novel and known RPGR isoforms were found to be
differentially regulated in several human tissues. In human retina, approximately 10% of RPGR
transcripts are alternatively spliced between exons 9 and 15. CONCLUSIONS. These findings show that
splicing of RPGR is precisely regulated in a tissue-dependent fashion and suggest that mutations in
RPGR frequently interfere with the expression of alternative transcript isoforms. These results implicate
the importance of RPGR transcript analysis in patients with RP. The authors further discuss RPGR
splicing as a modifier of different disease phenotypes described in patients with XlRP.  
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PURPOSE. The majority of patients with X chromosome-linked
retinitis pigmentosa (XlRP) carry mutations in the RPGR gene.
The authors studied whether patients with RPGR mutations
show additional splice defects that may interfere with RPGR
properties.
METHODS. Patient-derived cell lines with RPGR mutations were
raised in suspension. To verify mutations, direct sequencing of
PCR products was performed. Patient-specific alterations in
RPGR splicing were analyzed by RT-PCR and confirmed by
sequencing. Tissue-specific expression levels of RPGR splice
variants were quantified by real-time PCR using pools of differ-
ent human donor tissues.
RESULTS. The authors analyzed the splicing of RPGR in seven RP
patient-derived lymphoblastoid cell lines carrying hemizygous
RPGR mutations. In three patient cell lines, they identified and
characterized splice defects that were present in addition to a
mutation. These splice defects were likely to interfere with
normal RPGR properties. Furthermore, they identified four
novel RPGR transcripts, either containing a new exon termed
11a or skipping the constitutive exons 12, 14, and 15. Novel
and known RPGR isoforms were found to be differentially
regulated in several human tissues. In human retina, approxi-
mately 10% of RPGR transcripts are alternatively spliced be-
tween exons 9 and 15.
CONCLUSIONS. These findings show that splicing of RPGR is
precisely regulated in a tissue-dependent fashion and suggest
that mutations in RPGR frequently interfere with the expres-
sion of alternative transcript isoforms. These results implicate
the importance of RPGR transcript analysis in patients with RP.
The authors further discuss RPGR splicing as a modifier of
different disease phenotypes described in patients with XlRP.
(Invest Ophthalmol Vis Sci. 2010;51:1628–1635) DOI:10.1167/
iovs.09-4031
Retinitis pigmentosa (RP) is a clinically and genetically het-erogeneous eye disorder leading to the degeneration of
photoreceptors in the human retina. Most patients with RP
exhibit difficulties in dark adaptation and night blindness in
adolescence and loss of midperipheral vision in young adult-
hood. In general, the rod photoreceptors degenerate first,
causing a loss of peripheral vision. During progression of the
disease, cone photoreceptors may also die, which ultimately
leads to loss of central vision and complete blindness.1 The
disease prevalence is approximately 1 in 3000 to 4000 people,
affecting more than 1.5 million worldwide. More than 35
RP-associated genes have been identified so far. Most of them
have been reported to be involved in phototransduction, basic
metabolic pathways, maintenance of photoreceptor morphol-
ogy, transcriptional regulation, or pre-mRNA splicing, as re-
viewed by Kennan et al.2
The inheritance pattern of RP can be autosomal recessive
(arRP), autosomal dominant (adRP), or X-linked (XlRP). The
latter is considered to cause the clinically severest form of RP.
Approximately 60% to 70% of all X-linked families show muta-
tions in the retinitis pigmentosa GTPase regulator (RPGR)
gene.3,4 Here, the majority of mutations were found in the
alternatively spliced exon ORF15, whereas exons 1 to 15 carry
a minor portion of all RPGR mutations.5–9 A few mutations in
exon 1 to 15 of RPGR have been associated with additional
nonocular manifestations. In a family with XlRP described
previously, two members displayed a complex phenotype
combining primary ciliary dyskinesia and retinitis pigmentosa.
In this case, aberrant splicing of RPGR was found in nasal
epithelial cells because of a 57-bp deletion in exon 6.10 Addi-
tionally, a syndromic phenotype including RP, hearing defects,
and severe sinorespiratory infections has been associated with
mutations in RPGR exon 64 or exon 8.11 These reports indicate
that the function of the widely expressed RPGR is important
not only for the retina but also for other tissues.
RPGR transcripts have been identified in several human
tissues (e.g., retina, brain, lung, kidney, and testis).12–14 More-
over, transcript isoforms of RPGR have been described and
occasionally found to be expressed in a tissue- or cell-type-
specific manner. One of these transcripts includes the alterna-
tive exon 15a,14 and another contains exon 15b.15 RPGR
isoforms may also show skipping of constitutive exons (e.g.,
exons 14 and 15).14 Transcripts containing the alternative
exon 9a produce a truncated protein that is predominantly
expressed in human cone photoreceptors.16
The effect of many RPGR mutations on protein structure
has been predicted.5,6,12–15,17 However, as has been described
for other genes, a large fraction of exonic mutations also leads
to splice defects by disruption of constitutive and regulatory
splice-relevant sequences.18 Because mutation-induced alter-
ations of splice patterns in RPGR may contribute to the patho-
genic mechanism for RP,16,19–22 we analyzed the effect of
different RPGR mutations on splicing. Four novel RPGR iso-
forms were identified that showed differential expression in
several tissues. Our results suggest that RPGR splicing is part of
the pathogenic mechanism underlying the complex disease of
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RP. This further raises the possibility that alterations in RPGR
splicing act as modifiers of the disease expression.
MATERIALS AND METHODS
Cell Culture
Splicing of RPGR was analyzed in seven Epstein-Barr virus-transformed
lymphoblastoid cell lines (LCLs) derived from the blood of male pa-
tients with RP (Table 1) and an unaffected male control. Informed
consent was obtained from each patient and the unaffected control in
this study, and all were treated in accordance with the Declaration of
Helsinki. Additional family members were not available for further
tests. LCLs were grown in RPMI 1640 medium (LabForce, Nunningen,
Switzerland), 10% FBS (LabForce), 1.1% penicillin-streptomycin (Lab-
Force), and 1.3% L-glutamine (LabForce) at 37°C, 5% CO2 by using
75-cm2 cell culture flasks (Techno Plastic Products, Trasadingen, Swit-
zerland). Between 8  106 and 4  107 cells were pelleted by centrif-
ugation at 4°C with 2000g for 10 minutes. The pellets were washed
with 1 DPBS (LabForce), snap frozen, and stored at 80°C before
extraction of DNA or RNA. To inhibit nonsense-mediated mRNA decay
(NMD), 1  106 cells/mL were incubated in 30 g/mL cycloheximide
(Sigma-Aldrich, Schnelldorf, Germany) at 37°C, 5% CO2 in 25-cm
2 cell
culture flasks (Techno Plastic Products) for 4 hours, as previously
described.23
RNA Extraction, cDNA Synthesis, and RT-PCR
To extract total RNA from LCLs, the cells were disrupted using either
spin columns (QIAshredder; Qiagen, Hombrechtikon, Switzerland) or
a rotor-stator homogenizer (Ultra-Turrax T8; IKA Analysetechnik
GmbH, Heitersheim, Germany). Subsequently, RNA was isolated with
kits (RNeasy Mini or Midi; Qiagen) according to the manufacturer’s
instructions. RNA quality was verified with an electrophoresis analysis
system (2100 Bioanalyzer; Agilent, Basel, Switzerland), and the amount
was determined with a photometer (ND-1000; NanoDrop, Litau, Swit-
zerland). One thousand nanograms of total RNA were randomly primed
before reverse transcription by reverse transcriptase (Superscript III; In-
vitrogen, Basel, Switzerland) according to the manufacturer’s protocol. To
verify correct splicing of the RPGR transcripts, RT-PCR reactions were
performed with 50 ng cDNA, as described previously.16 Primers used in
the RT-PCR assays are shown in Supplementary Table S1, available at
http://www.iovs.org/cgi/content/full/51/3/1628/DC1. RT-PCR products
were confirmed by sequencing. Each RT-PCR experiment was replicated
three times using RNA from independently grown LCL cells.
Quantitative Real-Time PCR of Alternative RPGR
Transcript Variants
Quantifications of RPGR transcript levels were performed by quanti-
tative real-time PCR (HT 7900 TaqMan using Assay by Design MGB
FAM-TAMRA-labeled probes; Applied Biosystems, Rotkreuz, Switzer-
land). To study the expression of RPGR transcript isoforms in several
tissues, total RNA from pools of different human donor tissues (brain,
n  5; kidney, n  5; lung, n  3; retina, n  25; testis, n  39) was
purchased from Becton Dickinson (Allschwil, Switzerland) or BioCat
(Heidelberg, Germany). Three to four cDNA batches were indepen-
dently generated and analyzed from each tissue.
We designed probes (TaqMan; Applied Biosystems) to quantify
exon/exon boundaries for each alternative RPGR transcript isoform
and a corresponding probe for the constitutive transcript. Probes
specific to the constitutive transcript of RPGR were used as endoge-
nous controls. Their comparability was tested according to the manu-
facturer’s instructions. Each quantification reaction was technically
replicated at least four times and gave results with amplification curves
starting between 25 and 30 cycles. Using equal amounts of cDNA per
sample, Ct values of the constitutive transcript did not differ signifi-
cantly between tissues (errors represent 95% confidence intervals
[CIs]): retina 26.3 (0.86), brain 25.75 (1.45), lung 25.9 (0.37),
kidney 26.53 (1.23), and testis 25.6 (1.49). The outcome was
analyzed using specialized software (SDS 2.2; Applied Biosystems).
Expression levels of the tested tissues or LCLs were normalized to
human retina or an unaffected male control, respectively; 95% CIs
were calculated from three to four independently generated samples.
DNA Purification and Sequencing
RT-PCR products were gel-extracted (QIAquick Gel Extraction Kit;
Qiagen). Gel-purified DNA was either cloned into the vector (pCRII-
TOPO; Topo TA Cloning Kit Dual Promoter; Invitrogen) according to
the manufacturer’s instructions or sequenced directly. DNA from LCLs
was extracted as previously described.24 To identify or verify muta-
tions in patient cell lines, exons of RPGR were amplified by PCR
(HotFirePol; Solis Biodyne, Tartu, Estonia) and sequenced directly
(sequencing analyzer, model 3100; Applied Biosystems). Mutations
were designated according to the nomenclature provided by the hu-
man genome variation society (www.hgvs.org). The numbering of
mutations refers to the human RPGR reference sequence
NM_001034853 for cDNA or reference assembly NC_000023.9 (range,
38013367–38071732) for genomic DNA from the National Center for
Biotechnology Information database. The potential effect of exonic
mutations on exonic splicing enhancer (ESE) binding sites was ana-
lyzed (ESEfinder 3.0; http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.
cgi?process  home).
RESULTS
We followed the hypothesis that splice defects frequently
occur in addition to mutations found in RPGR. To detect splice
TABLE 1. RPGR Mutations of Analyzed Lymphoblastoid Cell Lines Derived from Male Patients
with X1RP
Patient ID
Mutation in
Exon/Intron Sequence Alteration
Consequence of
Sequence Alteration
2616 Intron 1 c.281GA Potential splice defect
4767* Exon 5 c.389TG p.Phe130Cys
Exon 11a g.31259GA†‡ Splice defect/p.Asp484Asn
2884 Exon 7 c.706CT p.Glu236X
2555 Exon 8 c.823GA p.Gly275Ser
2603 Exon 8 c.823GA p.Gly275Ser
2549 Exon 11 c.1399CT p.Gln467X
2550§ Exon 11 c.1402_1405delCCAG p.Arg468fs
cDNA reference sequence: NM_001034853.
* Female carriers are affected in this family.
† Genomic DNA reference sequence: NC_000023.9 (range, 38013367–38071732).
‡ Mutation is first described in this report.
§ Patient has a mild hearing impairment (Rosenberg T, personal communication, 2007–2008).
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defects, we established RT-PCR assays that allow analysis of
RPGR transcripts and screened LCLs derived from seven male
patients with RP affected by known hemizygous RPGR muta-
tions (Table 1). The LCLs used were not preselected for pos-
sible splice defects.
Splice Site Mutation in RPGR Intron 1
In patient cell line LCL 2616, RT-PCR amplification of exons 1
through 5 yielded no product (Fig. 1). In contrast, using prim-
ers that bind to exons 2 and 5 resulted in a fragment, although
weaker than that of the unaffected control and other cell lines.
Furthermore, RT-PCR with primer combinations specific to
downstream located exons confirmed that LCL 2616 shows
reduced RPGR transcript amounts (Fig. 1). These analyses
suggested the presence of a mutation affecting normal tran-
script processing in this patient cell line. Indeed, a mutation at
the first base of intron 1 (c.281GA; Table 1) was present in
LCL 2616. This mutation is expected to result in a splice defect.
Although extensively assayed, we were not able to amplify
splice products between exon 1 and 2. These results suggest
defective splicing of RPGR because of the mutation
c.281GA leading to a reduced amount of transcripts. It
further raises the possibility that the translation of RPGR may
start from exon 3, where the next in-frame start codon is
located.
The Novel RPGR Exon 11a
We performed RT-PCR analyses of RPGR transcripts containing
exons 11 through 15 in all patient cell lines listed in Table 1. In
LCL 4767 we detected an additional amplicon of approxi-
mately 700 bp in length by conventional RT-PCR (Fig. 2A).
Sequencing revealed that this fragment includes a novel exon
spliced between exons 11 and 12. It was thus termed exon
11a. It contains 160 nucleotides and starts 1139 bp down-
stream of the splice donor site of exon 11 (Fig. 2B). The
resultant new coding sequence contains a stop codon.
These results suggested elevated expression levels of RPGR
transcripts containing exon 11a (RPGREx11a) in LCL 4767. We
confirmed this observation by quantitative RT-PCR and de-
tected a fourfold increased expression of RPGREx11a only in
this patient cell line (Fig. 2C). These results document a splice
alteration specific to LCL 4767.
The previously identified missense mutation in exon 5
(c.289TG, p.Phe130Cys; Table 1) in this patient13 is most
likely not causing the overexpression of exon 11a because of
the distance between the two affected exons. Therefore, we
searched for additional sequence alterations in exon 11a and
identified a GA transition at position 36 (g.31259GA), 15
bp upstream of the stop codon of exon 11a (Fig. 2D, Table 1).
The sequence alteration was not annotated as a single nucleo-
tide polymorphism (SNP) in databases (UCSC, ENSEMBL,
NCBI) and was not found in 300 ethnically matched control
alleles (Caucasians), suggesting a pathogenic nature of this
variant.
Application of the ESEfinder program to this sequence al-
teration predicted a novel binding site for the splice factor
SC35 only in the mutated exon 11a (Fig. 2D). Enhanced bind-
ing of SC35 to exon 11a may thus explain the significantly
elevated levels of RPGREx11a transcripts specifically found in
patient 4767.
RPGR Exon 12, 14, or 15 Skipping
RT-PCR analysis of RPGR transcripts, including exons 11
through 19, revealed two major isoforms either containing all
known exons or simultaneously skipping exons 14 and 15 (Fig.
3A). The control samples showed an additional band at 1000
bp (Fig. 3A). Cloning and sequencing of this band documented
that this amplicon is a mixture of two thus far unknown RPGR
isoforms that skip either exon 14 (RPGRskipEx14) or 15
(RPGRskipEx15).
Comparing all patient-derived cell lines, LCL 2550 showed
an alteration from the control splice pattern in conventional
RT-PCR analyses. We detected two additional fragments, both
migrating 92 bp below the two major products. As confirmed
by sequencing, these novel transcripts lack exon 12 of RPGR
(RPGRskipEx12; Fig. 3A).
Patient 2550 carries a deletion of 4 bp in exon 11
(c.1402_1405delCCAG, p.Arg468fs; Table 1).13 This deletion
affects positions 12 to 9 upstream of the last nucleotide of
exon 11, an exonic region spatially unrelated to the splice
donor site. Importantly, the deletion causes a frame-shift that
leads to a premature termination codon (PTC) in exon 12 (Fig.
3C). Because transcripts containing a PTC are susceptible to
NMD,25 we searched for such potential effects. To inhibit
NMD, we treated cells with cycloheximide (CHX) and com-
pared them with untreated cells. We found only in LCL 2550
that inhibition of NMD affects splicing and restores the ampli-
fication pattern identified in the control cell line (Fig. 3B).
These findings show that the 4-bp deletion in exon 11 causes
a PTC in exon 12 that activates partial degradation by NMD.
Interestingly, LCL 2550 showed a transcript combining
exon 12 skipping (deletion of 92 bp) and deleting 4 bp in exon
11. This combination restores the open reading frame in the
FIGURE 1. Characterization of a splice site mutation in LCL 2616.
RPGR transcript analysis in the patient cell line 2616 and the unaf-
fected control using different primer combinations that span the whole
RPGR transcript. DNA marker sizes are given in base pairs.
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RPGR transcript (Fig. 3C). Thus, a protein might be translated
that lacks amino acids coded by exon 12.
Tissue-Specific Expression Analysis
of RPGR Isoforms
Our studies identified the four novel RPGR transcripts
RPGREx11a, RPGRskipEx12, RPGRskipEx14, and RPGRskipEx15.
To verify whether they are also generated in human tissues
other than lymphoblastoid cell lines, transcript analysis was
performed by quantitative RT-PCR using cDNA from pools of
different human tissues, including retina, brain, lung, kidney,
and testis. In addition, we tested whether the expression of
previously reported RPGR isoforms also shows tissue-specific
variation. This included RPGREx9a, which has recently been
found to be expressed predominantly in cone photoreceptors
of the human retina16 and transcripts, simultaneously skipping
exons 14 and 15 (RPGRskipEx14/15).14 The assessment of iso-
form quantities was performed in comparison to the constitu-
tive transcript of RPGR.
Our data show that the abundance of each of the alternative
RPGR isoforms varied between 0.8% (RPGRskipEx12) and 2.7%
(RPGRskipEx14/15) within the retina (Fig. 4). In summary, we
document that in the human retina, approximately 10% of
RPGR transcripts are alternatively spliced between exons 9
and 15 (Fig. 4).
The amount of each alternative isoform also varied among
different tissues (Fig. 5). The highest levels of RPGREx11a
were observed in retina, whereas other tissues contained sig-
nificantly lower amounts (Fig. 5A). Furthermore, we detected
the highest expression of RPGRskipEx12 in lung and kidney and
found 10- to 12-fold lower amounts of this isoform in retina,
brain, and testis (Fig. 5B). Similarly, RPGREx9a transcripts
were expressed more greatly in lung and kidney than in retina
(Fig. 5E). The highest expression of the novel RPGR variant
RPGRskipEx14 was found in brain (Fig. 5C), whereas
RPGRskipEx15 expression was lowest in retina (Fig. 5D). Iso-
form RPGRskipEx14/15 exhibited the largest variation: it was 20
times more highly expressed in brain than in retina (Fig. 5F).
FIGURE 2. Overexpression of the RPGREx11a transcript isoform in patient cell line 4767. (A) RT-PCR amplification of RPGR transcripts containing
exons 11 through 15. Schematic drawings illustrate the exon composition of amplified RT-PCR products. Primer binding sites are indicated as
horizontal gray bars. DNA marker sizes are given in base pairs. (B) Sequence of the novel RPGR exon 11a and flanking intronic regions.
Nucleotides in gray represent exon 11a sequences, whereas deduced amino acids are indicated as single letter code above of each nucleotide
triplet. The stop codon is presented in italics, and coding sequences are shown in uppercase letters. The position mutated in patient 4767
(g.31259GA) is marked by a box. NC_000023.9 was used as reference sequence for genomic DNA (numbers at the right indicate the nucleotide
position). (C) Real-time quantitative RT-PCR of exon 11a expression levels detected in the unaffected control (I), in a pool of six LCLs carrying
hemizygous RPGR mutations (n  6) different from the sequence alteration in exon 11a (II) and in the patient cell line 4767 (III). Error bars
represent 95% CI calculated from cDNA batches generated from the RNA of three independently grown LCL cells. Asterisk indicates statistical
significance between measurements. (D) Electropherograms from parts of the exon 11a sequence of patient cell line 4767 and a control. Arrows
indicate the position of the mutation g.31259GA in patient 4767. The stop codon is shown in italics. Positions of putative binding sites for ESEs
SF2/ASF and SC35 are depicted as horizontal bars. The results suggest the existence of an additional SC35 binding site uniquely in the patient.
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Taken together, these findings show that the expression of
alternative RPGR transcripts varies significantly among and
within tissues. This indicates distinct tissue-specific RPGR
splicing that may confer specialized function of the different
isoforms.
DISCUSSION
Alternative splicing of pre-mRNA transcripts is considered to
be an important mechanism to increase protein variability from
a single gene.26 This process also acts on human RPGR and
generates alternative transcript isoforms, the expression of
which is spatially and temporally regulated.14–16
In this article, we describe four novel transcript isoforms of
RPGR termed RPGREx11a, RPGRskipEx12, RPGRskipEx14, and
RPGRskipEx15. We showed that all are expressed in a tissue-
dependent fashion, which suggests functional consequences.
The highest expression levels of both RPGRskipEx14 and
RPGRskipEx14/15 were detected in brain. Consequently, mis-
regulation of transcripts lacking exon 14 or exons 14 and 15
might disturb their function in brain. To date, no mutation in
RPGR has been described that shows a phenotypic manifesta-
tion in this tissue. However, only a few patients are known to
contain mutations in exon 14 or 15 (compare to http://rpgr.
hgu.mrc.ac.uk). Detailed clinical characterization of the brain
functions in these patients might add valuable information on
the phenotypic spectrum caused by mutations in RPGR.
Our data suggest that RPGR transcripts are differentially
spliced among tissues. They further show that the novel iso-
forms described herein are expressed at lower levels than the
constitutive transcript of RPGR. Nevertheless, a significant
portion of RPGR transcripts are alternatively spliced between
exons 9 and 15 in the retina. Because tissues are heterogenous
with respect to cell type, one possible explanation for our
observation is that only a fraction of cells within a given tissue
expresses a distinct isoform or that expression is cell type
specific. Similar observations have been published for RPGR
containing exon 9a.16 The corresponding protein of the exon
9a-containing transcript was predominantly present in cones of
the retina, suggesting a specialized function of this isoforms in
a subfraction of photoreceptors. It is a matter of future study to
evaluate whether the novel RPGR isoforms described herein
are also expressed by a specific cell type within distinct tissues.
Regulation of alternative and tissue-specific splicing is thought
to be controlled by proteins that stimulate or repress exon rec-
ognition. In general, such factors are called exonic or intronic
splicing enhancers (ESEs or ISEs) and silencers. Some of these
factors are expressed only in certain tissues and regulate splicing
of specific sets of pre-mRNAs.27 A well-known example is the
mammalian splicing factor NOVA-1, which is involved in the
control of alternative pre-mRNA splicing in neurons. This protein
binds specific intronic sequences of pre-mRNA targets through its
K-homology (KH) domains. NOVA-1 is reported to enhance the
inclusion of specific alternative exons into target transcripts and is
expressed in distinct populations of neurons in the brain.28 Tak-
ing this into account, we envision that factors with similar func-
tions might regulate the expression of alternative RPGR transcript
isoforms within tissues.
FIGURE 4. Relative abundance of alternative transcript isoforms of
RPGR in human retina. Expression levels of alternative variants are
displayed as percentages of the constitutive RPGR transcript in human
retina. Numbers in bars represent mean values given in percentages
Error bars represent confidence intervals of 95% CIs calculated from
three to four independently generated cDNA batches.
FIGURE 3. Upregulation of the novel RPGRskipEx12 transcript. (A) RT-
PCR amplification of exons 11 to 19 of the RPGR transcript. Schematic
drawings illustrate the sequence of amplified RT-PCR products. Each
RT-PCR product is marked by a number corresponding to the respec-
tive schematic drawing. Primer binding sites in exons 11 and 19 are
indicated by horizontal gray bars. Numbers at the left represent DNA
marker sizes and are given in base pairs. (B) RT-PCR of RPGR exons 11
to 19 of patient cell line 2550 and a control, either incubated with ()
or without () CHX to inhibit NMD. The RT-PCR reaction lacking a
template is indicated as H2O. (C) Graphical illustration of mutation-
induced mechanisms in patient cell line 2550 leading to detectable
levels of RPGRskipEx12 transcripts. The asterisk labels a premature
termination codon (PTC) in exon 12, which is generated in patient cell
line 2550 because of the 4-bp deletion in exon 11. The PTC causes
reduced expression levels of transcripts, including exon 12, by NMD
(upper). In contrast, transcripts lacking exon 12 in combination with
the 4-bp deletion escape NMD because of preservation of the open
reading frame (lower).
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A different mechanism of gene regulation acts through
NMD, which constitutes a posttranscriptional regulatory pro-
cess. We found that NMD reduces the amount of a mutated
RPGR transcript that contains a PTC. Of note, NMD may also
act on nonmutated transcripts.29–31 In addition, it has been
documented that it can be active in a tissue-specific man-
ner.32–34 These observations provide a possible explanation
why RPGR isoforms were found to be expressed at elevated
levels among tissues.
Interestingly, most RPGR isoforms truncate the deduced
protein downstream of the regulator of chromosome conden-
sation 1-like domain (RCC1). The RCC1-like domain of RPGR
FIGURE 5. Multi-tissue expression analyses of novel and previously reported RPGR transcript isoforms. Quantitative RT-PCR to detect expression of (A)
RPGREx11a, (B)RPGRskipEx12, (C)RPGRskipEx14, (D)RPGRskipEx15, (E)RPGREx9a, and (F)RPGRskipEx14/15 from different donor tissues. For quantification
of the novel RPGR transcript isoform, we used expression of the constitutive RPGR transcript as endogenous control. Subsequently, relative expression
levels of each isoform were compared with human retina (retinal levels were set to 1). Asterisks illustrate significance between measurements as
described in the Results section. Error bars represent 95% CIs calculated from three to four independently generated cDNA batches.
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includes exons 2 through 11.5,14,16 This domain has been
shown to bind four different interaction partners: RPGR inter-
acting protein 1 (RPGRIP1), prenyl-binding protein delta, and
structural maintenance of chromosomes 1 and 3 proteins.35–38
Different RPGR protein isoforms have been shown to be asso-
ciated with a multiprotein complex, which is thought to be
involved in intraphotoreceptor protein transport through the
connecting cilium.39 We have previously shown that exon 9a
containing RPGR transcripts gives rise to a truncated protein
that binds distinct isoforms of RPGRIP1.16 On the assumption
that the other transcript variants described herein are also
translated, our data support a model that predicts binding of
distinct RPGR isoforms to different sets of interaction partners
to form various functionally unique protein complexes. Muta-
tions that modify distinct RPGR isoforms would influence the
formation of these complexes. Cases have been reported in
which RPGR mutations in the RCC1-like domain (affecting
exons 6 and 8) are associated with nonocular manifesta-
tions.4,10,11 These reports further support our hypothesis that
RPGR isoform-specific protein complexes fulfill tissue-specific
functions.
The disease phenotype in patients affected by RPGR muta-
tions can be highly variable even within one family. These
observations imply the existence of modifiers that influence
the severity of the disease. Here we showed that not only does
a mutation in RPGR affect the predicted amino acid sequence
of the protein, it may also result in missplicing or altered
regulation of specific transcripts. Given that alternative splic-
ing is precisely regulated in a tissue-specific and a developmen-
tal stage-dependent manner, changes in this process may cause
or modify disease symptoms.40 Taking this into account, our
results suggest that defects in RPGR splicing could modify the
disease phenotype of RP. Several examples for splicing-in-
duced modifications of a disease have been reported.41
We have identified alterations in the splicing of RPGR in 3
of 7 cell lines of patients with RP. Our findings implicate the
importance of including the analysis of RPGR splicing in pa-
tients with retinal degenerations and associated phenotypes.
Furthermore, patient-derived cell lines showed splice alter-
ations in RPGR isoforms that are differentially regulated among
distinct human tissues. Thus, not only could a change in the
expression of these isoforms affect the retina, it could also
disrupt their function in other tissues.
In patient cell line 2550, we detected elevated levels of
RPGRskipEx12 transcripts. The deletion of 4 bp in combination
with exon 12 skipping abolishes the deleterious effects of the
frame-shift. Therefore, these transcripts can now escape deg-
radation by NMD and may be expressed as a truncated RPGR
protein in the patient. The splice defect is likely to take place
in most tissues, indicating that more than the retina is affected.
Interestingly, there is evidence that patient 2550 has a mild
hearing impairment. The audiogram showed a dip with high-
frequency pure tones (Rosenberg T, personal communication,
2007–2008). Although speculatory, the nonocular manifesta-
tion of auditory problems might be the result of the expression
of this aberrant protein isoform. It has been observed in a
different patient (patient ID 2557) that a 6.4-kb deletion within
RPGR,17 in addition to a 1-bp deletion at the 3 end of exon
ORF15 (c.3395delA),6 may affect the audiogram.42 Neverthe-
less, an age-related effect on hearing in these patients cannot
be excluded. It would further be of interest to clarify whether
the respiratory function of patient 2550 is impaired because
our expression data suggest that RPGRskipEx12 transcripts
might be relevant in lung.
We showed that patient 4767 expresses increased levels of
RPGREx11a, likely because of a sequence alteration in exon
11a. This novel mutation is predicted to change the activity of
a splice enhancer site of SC35, which might control the fre-
quency of exon 11a inclusion into the transcript. SC35, a
ubiquitously expressed splice factor, has been shown to in-
crease the integration of a target exon by mediating specific
interactions with components of the spliceosome.43 Mutations
that increase the binding affinity for an exonic splicing en-
hancer have already been associated with other human dis-
eases, e.g., frontotemporal dementia with Parkinsonism-chro-
mosome 17 type (FTDP-17)44 and a cardiac phenotype of Fabry
disease.45 We demonstrated that the expression of exon 11a
was significantly increased only in cell line 4767. Toxic effects
leading to premature death of photoreceptors might be caused
by overexpression of a distinct RPGR isoform, a mechanism
similar to that proposed by us for RPGREx9a.16 Furthermore,
the overexpression of RPGR in mice also leads to a severe
phenotype in sperm flagella, resulting in male infertility.46
Interestingly, the family pedigree of patient 4767 shows
over a period of six generations an inheritance pattern by
which female carriers are also affected (data not shown). We
cannot exclude that this mode of inheritance is caused by
skewed X-inactivation in affected females. However, this mech-
anism has never been found to influence the phenotype of
female carriers of RPGR mutations6,47,48 and, thus, is unlikely
to be a common mechanism explaining symptomatic female
carriers. In the patient described herein, either a cumulative or
a separate effect of the two identified sequence alternation in
exons 5 and 11a might be the cause of the disease.
Taken together, the results reported here provide new
insights into alternative splicing of RPGR and will help to
elucidate its role in distinct tissues. Moreover, RPGR splice
defects provide a pathogenic mechanism newly associated
with RPGR, which implies that classical and syndromic pa-
tients with RP should be analyzed for alterations in RPGR
splicing.
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